Adicet Bio Inc (ACET)
1.675
-0.14
(-7.46%)
USD |
NASDAQ |
Apr 26, 16:00
1.675
0.00 (0.00%)
After-Hours: 20:00
Adicet Bio Enterprise Value: -11.01M for April 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 25, 2024 | -11.01M |
April 24, 2024 | -5.672M |
April 23, 2024 | 12.81M |
April 22, 2024 | 4.597M |
April 19, 2024 | 0.4893M |
April 18, 2024 | 6.651M |
April 17, 2024 | 26.78M |
April 16, 2024 | 20.21M |
April 15, 2024 | 21.03M |
April 12, 2024 | 17.74M |
April 11, 2024 | 24.31M |
April 10, 2024 | 16.92M |
April 09, 2024 | 28.42M |
April 08, 2024 | 19.38M |
April 05, 2024 | 25.14M |
April 04, 2024 | 27.60M |
April 03, 2024 | 25.96M |
April 02, 2024 | 34.17M |
April 01, 2024 | 37.46M |
March 28, 2024 | 33.35M |
March 27, 2024 | 31.71M |
March 26, 2024 | 24.31M |
March 25, 2024 | 21.03M |
March 22, 2024 | 20.21M |
March 21, 2024 | 7.883M |
Date | Value |
---|---|
March 20, 2024 | 16.10M |
March 19, 2024 | 7.062M |
March 18, 2024 | 0.4893M |
March 15, 2024 | 4.597M |
March 14, 2024 | 8.705M |
March 13, 2024 | 24.90M |
March 12, 2024 | 33.93M |
March 11, 2024 | 42.13M |
March 08, 2024 | 39.67M |
March 07, 2024 | 36.39M |
March 06, 2024 | 37.21M |
March 05, 2024 | 30.65M |
March 04, 2024 | 35.57M |
March 01, 2024 | 37.21M |
February 29, 2024 | 33.11M |
February 28, 2024 | 31.47M |
February 27, 2024 | 36.39M |
February 26, 2024 | 38.85M |
February 23, 2024 | 42.95M |
February 22, 2024 | 40.49M |
February 21, 2024 | 61.00M |
February 20, 2024 | 74.13M |
February 16, 2024 | 81.52M |
February 15, 2024 | 86.44M |
February 14, 2024 | 78.24M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-146.46M
Minimum
Sep 29 2023
628.77M
Maximum
Nov 11 2022
141.80M
Average
118.78M
Median
Enterprise Value Benchmarks
Sagimet Biosciences Inc | 30.21M |
Catalyst Pharmaceuticals Inc | 1.593B |
Codexis Inc | 121.19M |
Annexon Inc | 153.50M |
Taysha Gene Therapies Inc | 326.71M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -29.49M |
Total Expenses (Quarterly) | 31.57M |
EPS Diluted (Quarterly) | -0.68 |
Earnings Yield | -197.6% |
Normalized Earnings Yield | -68.66 |